GlassScriptPhysician profile
Samuel A Twedt
NPI 1518451137
$3,083.24
in general payments reported to CMS, 2019-2025
19 companies · $546 in 2025
The $546 reported for 2025 was more than what 75% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $294 · 2022: $507 · 2023: $1,084 · 2024: $653 · 2025: $546.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,283.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,282.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $907.11 | 2021-2025 | Vraylar, Qulipta, Ubrelvy |
| Astrazeneca Pharmaceuticals LP | $599.11 | 2022-2025 | Breztri, Farxiga |
| Novo Nordisk INC | $386.79 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $266.82 | 2022-2025 | Mounjaro, Jardiance, Zepbound |
| Amgen INC. | $174.93 | 2021-2025 | Repatha, Otezla, Evenity |
| Nestle Healthcare Nutrition INC. | $168.80 | 2021 | |
| Pfizer INC. | $139.73 | 2021-2024 | |
| Exact Sciences Corporation | $79.89 | 2023-2024 | Cologuard Collection Kit |
| Almatica Pharma LLC | $58.00 | 2023 | Loreev Xr |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $48.15 | 2025 | Caplyta |
| Idorsia Pharmaceuticals US INC | $45.56 | 2023 | Quviviq |
| Glaxosmithkline, LLC. | $45.36 | 2023 | Shingrix, Boostrix, Arexvy |
| Kowa Pharmaceuticals America, INC. | $31.09 | 2022-2024 | Livalo |
| Astellas Pharma US INC | $28.75 | 2021-2024 | Veozah |
| Neurocrine Biosciences, INC. | $25.12 | 2023 | Ingrezza |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Specialty L.P. | $24.70 | 2022 | |
| Phathom Pharmaceuticals, INC. | $22.36 | 2024 | Voquezna |
| Electromed, INC. | $20.41 | 2024 | Smartvest |
| Grt US Holding, INC. | $10.56 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samuel Twedt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.